Clinical Trials
Overview
We are committed to developing curative allogeneic cell therapies through rigorous clinical trials that assess the safety and efficacy of our investigational medicines for patients with cancer and autoimmune and inflammatory diseases. We are dedicated to upholding the highest standards throughout our trials to ensure patient safety and well-being are prioritized, and are grateful to the patients, families, hospitals and clinics that participate in our clinical studies.
Current and Planned Trials
ELiPSE-1: Phase 1 Clinical Trial
A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell lymphomas.
Now Recruiting
Learn more about Century’s current Phase 1 clinical trial, ELiPSE-1, with study ID number: NCT05336409 at clinicaltrials.gov.
Patient Flyer
Download
CALiPSO-1: Phase 1 Clinical Trial
A multicenter, dose-finding study to evaluate the safety and efficacy of CNTY-101 in patients with moderate to severe systemic lupus erythematosus (SLE).
Not Yet Recruiting: Trial Expected to Initiate in the First Half of 2024
Learn more about Century’s planned Phase 1 clinical trial, CALiPSO-1, with study ID number: NCT06255028 at clinicaltrials.gov.